Immune restoration and CD4+ T-cell function with antiretroviral therapies

AIDS

Volumn 15, Issue SUPPL. 2, 2001, Pages

  Lederman, M M ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

CD4; HAART; Immune restoration; Lymphocyte proliferation; Vaccine

Indexed keywords

ANTIRETROVIRUS AGENT;

CHRONICITY; CONFERENCE PAPER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; IMMUNIZATION; IMMUNOTHERAPY; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; LYMPHOID TISSUE; MORTALITY; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; THYMUS; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; HIV-1; HUMANS; LYMPHOCYTE ACTIVATION;

EID: 0035092899     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200102002-00003     Document Type: Conference Paper

References (50)

1. + T cell homeostasis and function in advanced HIV disease
2. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: Results of AIDS Clinical Trials Group Protocol 315
3. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation
4. Early reduction of immune activation in lymphoid tissue following highly active HIV therapy
5. In vivo analysis of Fas/FasL interactions in HIV-infected patients
6. Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues
7. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy
8. Changes in thymic function with age and during the treatment of HIV infection
9. Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy
10. Thymic size and lymphocyte restoration in HIV infected patients following 48 weeks of therapy with zidovudine, lamivudine and ritonavir
11. + T lymphocytes in HIV-1 infection as measured by Ki-67 antigen
12. + T cells correlate with plasma human immunodeficiency virus (HIV-1) RNA level in HIV-1 infection
13. + T-cell renewal in early HIV-1 infection: Effect of highly active anti-retroviral therapy
14. HIV infection perturbs DNA content of lymphoid cells: Partial correction after 'suppression' of virus replication
15. + T-cell pool during HIV-1 infection and triple combination therapy
16. Rapid turnover of T lymphocytes in SIV-infected rhesus macaques
17. + T cell turnover in HIV-infected patients
18. Loss of primitive hematopoietic progenitors in patients with human immunodeficiency virus infection
19. HIV induces thymus depletion in vivo
20. Protease inhibitor and triple-drug therapy: Cellular immune parameters are not restored in pediatric AIDS patients after 6 months of treatment
21. HAART in HIV-infected patients: Restoration of antigen-specific CD4 T-cell responses in vitro is correlated with CD4 memory T-cell reconstitution, whereas improvement in delayed type hypersensitivity is related to a decrease in viraemia
22. Long-term evaluation of T-cell subsets and T-cell function after HAART in advanced stage HIV-1 disease
23. Long-lastlng recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease
24. Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease. Immunology Study Group of Spanish EARTH-1 Study
25. Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV- 1 antigens
26. Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease
27. Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen
28. Effects of HAART plus an inactivated immunogen on LPR to HIV antigens
29. Absence of recoverable infectious virus and unique immune responses in an asymptomatic HIV+ long-term survivor
30. + T cell responses associated with control of viremia
31. Different immunologic profiles characterize HIV infection in highly active antiretroviral therapy-treated and antiretroviral-naïve patients with undetectable viraemia
32. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research
33. + T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression
34. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: Results from the EuroSIDA study
35. Natural history of HIV infection in the era of combination antiretroviral therapy
36. Combination antiretroviral therapy and incidence of AIDS-related malignancies
37. Effect of antiretroviral therapy on recent trends in selected cancers among HIV-infected persons
38. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study
39. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Swiss HIV Cohort Study
40. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy
41. Human immunodeficiency virus 1 protease inhibitors in clinical practice: Predictors of virological outcome
42. HIV-1 protease inhibitor ritonavir modulates susceptibility to apoptosis of uninfected T cells
43. Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4(+) T cells and decreases their susceptibility to apoptosis in vitro and in vivo
44. Anitiretrovial treatment: On and off
45. Virologic and immunologic evaluation of structured treatment interruptions (STI) in patients experiencing long-term virologic failure
46. Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response
47. Discordant CD4/RNA responses to HAART are strongly associated with high baseline CD4 count and low HIV RNA: Analysis of 406 naïve patients
48. Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen
49. Characterizing viral dynamics in HIV-1 infected patients treated with combination antiretroviral therapy: Relationship to host-specific factors, cellular restoration and virological endpoints
50. Poor CD4 T-cell responses after suppression of HIV replication may reflect thymic failure